OverTTuRe: Characteristics, Treatment Patterns and Outcomes of Patients With ATTR Amyloidosis

Launched by ASTRAZENECA · Apr 3, 2024

Keywords

ClinConnect Summary

The OverTTuRe clinical trial is looking at how patients with ATTR amyloidosis experience their disease before and after they are diagnosed. This study aims to gather real-world information about the characteristics of these patients, the treatments they receive, and the effects of the disease on their daily lives, including their health-related quality of life and ability to perform everyday activities. By understanding these factors, researchers hope to improve the care and support for people living with ATTR amyloidosis.

To participate in this study, individuals must be over 18 years old and have a confirmed diagnosis of amyloidosis, which can be shown by a specific diagnosis code, treatment records, or a biopsy that confirms the presence of the disease. Participants will be asked to share their experiences and undergo assessments related to their health and daily living. The trial is currently recruiting and welcomes all genders, providing a chance for patients to contribute valuable information that may benefit others with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged \>18 years at study index date AND
• • A reported diagnosis code for amyloidosis OR
• • A claim for ATTR-specific treatment OR
• • A positive biopsy for amyloidosis and positive immunostaining result of biopsy for ATTR
• Exclusion Criteria:
• • Evidence of primary (AL) and secondary (AA) amyloidosis AND/OR
• • At least one claim/procedure code for stem cell transplant or at least two claims/procedure codes for chemotherapy and autoimmune disease drugs which may represent AL (primary) or AA (secondary) amyloidosis treatments